Holocene Advisors LP Makes New Investment in STAAR Surgical (NASDAQ:STAA)

Holocene Advisors LP purchased a new position in STAAR Surgical (NASDAQ:STAA - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 29,509 shares of the medical instruments supplier's stock, valued at approximately $1,096,000. Holocene Advisors LP owned 0.06% of STAAR Surgical as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Erste Asset Management GmbH bought a new position in STAAR Surgical in the third quarter worth $788,000. American Capital Management Inc. raised its holdings in STAAR Surgical by 42.9% in the third quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier's stock worth $19,051,000 after purchasing an additional 154,037 shares in the last quarter. FMR LLC raised its holdings in STAAR Surgical by 79.3% in the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after purchasing an additional 3,136 shares in the last quarter. Larson Financial Group LLC raised its holdings in STAAR Surgical by 78.3% in the third quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier's stock worth $181,000 after purchasing an additional 2,135 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in STAAR Surgical in the third quarter worth $463,000. Hedge funds and other institutional investors own 96.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Stifel Nicolaus decreased their price objective on STAAR Surgical from $50.00 to $44.00 and set a "buy" rating for the company in a report on Monday, August 26th. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a report on Thursday, October 31st. Canaccord Genuity Group reduced their price target on STAAR Surgical from $41.00 to $31.00 and set a "hold" rating for the company in a report on Friday, November 1st. Finally, Stephens upgraded STAAR Surgical to a "hold" rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical has a consensus rating of "Hold" and an average target price of $43.33.

STAAR Surgical Price Performance

NASDAQ STAA traded up $0.07 during trading hours on Friday, hitting $25.31. The company's stock had a trading volume of 478,763 shares, compared to its average volume of 577,389. STAAR Surgical has a 12 month low of $25.04 and a 12 month high of $52.68. The company's 50 day simple moving average is $29.90 and its two-hundred day simple moving average is $35.53. The company has a market cap of $1.25 billion, a P/E ratio of 57.52 and a beta of 0.59.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.